$62b buyout bid

US healthcare giant Johnson & Johnson will buy Swiss biotech company Actelion in a $US30 billion ($F62b) all-cash deal that includes spinning off Actelion’s research and development pipeline, the companies said on Thursday. The biggest European drugs takeover in 13 years gives J&J access to the Swiss group’s range of high-price, high-margin medicines for rare […]

Continue reading this article with a Fiji Times online membership.

More Stories